Aquestive Therapeutics, Inc. filings document the regulatory, financial, governance, and capital-structure disclosures of a specialty pharmaceutical company built around oral-film drug delivery, proprietary product candidates, and CDMO/licensee manufacturing. Its 8-K reports include FDA communications and Regulation FD materials for Anaphylm™, financial results, investor presentations, and material agreements related to revenue-sharing, warrants, and common-stock purchase commitments.
Proxy materials describe annual-meeting voting matters, director elections, executive compensation, auditor ratification, and board governance. Other current reports record officer-transition matters, compensatory arrangements, exhibits, and product-development updates tied to the company’s regulatory strategy.
Aquestive Therapeutics insider Daniel R. Barber filed a notice of proposed sales of 25,000 shares of common stock of AQST, with an aggregate market value of $106,250.00, expected on August 17, 2026. The shares relate to Restricted Stock Units originally dated March 9, 2026. The filing also lists prior 10b5-1 plan sales of AQST common stock during the past three months.
Aquestive Therapeutics reported higher revenues but continued losses for the quarter and six months ended June 30, 2026. Quarterly revenue rose to $13,819 from $10,003, and six‑month revenue increased to $28,265 from $18,723, driven largely by manufacture and supply and higher license and royalty revenue, including $5,000 of Zevra‑related royalties.
Loss from operations narrowed to $8,223 from $11,368 for the quarter and to $12,427 from $30,733 for the six months, but a $11,683 loss on extinguishment of debt associated with refinancing 13.5% notes with a new Oaktree $55,000 Term Loan Facility increased quarterly net loss to $22,864. Six‑month net loss improved to $30,921 from $36,478.
Cash and cash equivalents were $98,490 at June 30, 2026, down from $121,169 after $24,247 of operating cash use and debt retirement costs, partly offset by equity raised through the ATM facility and new debt proceeds. Total liabilities exceeded assets, resulting in a stockholders’ deficit of $56,586, and the company carried $51,886 of royalty obligations linked to future Anaphylm and Libervant sales. Management states that existing cash, expense management, and capital markets access provide liquidity for at least the next twelve months.
Aquestive Therapeutics reported second quarter 2026 results with total revenues of $13.8 million, up from $10.0 million a year earlier, driven mainly by higher manufacture and supply revenue and increased license and royalty revenue. Manufacture and supply revenue rose to $11.9 million, while royalty-based products, including Sympazan, contributed to growth as manufacturing volumes increased to about 48 million doses from 37 million in the prior-year quarter.
GAAP performance weakened as the company recorded a net loss of $22.9 million versus $13.5 million last year, largely due to a $11.7 million one-time loss on extinguishment of 13.5% notes and higher selling, general and administrative expenses. However, non-GAAP adjusted EBITDA loss improved to $5.2 million from $9.3 million. Cash and cash equivalents were $98.5 million as of June 30, 2026, though the balance sheet showed a stockholders’ deficit of $56.6 million alongside substantial debt and royalty obligations.
Strategically, Aquestive completed the human factors and pharmacokinetic studies needed to address the FDA Complete Response Letter for Anaphylm and reaffirmed plans to resubmit the NDA in Q3 2026, seek ex‑U.S. approvals starting in late 2026, and continue advancing its AdrenaVerse™ epinephrine platform, including AQST‑108 for dermatologic indications. The company maintained its 2026 guidance for total revenue of $46–$50 million and non‑GAAP adjusted EBITDA loss of $35–$30 million.
Aquestive Therapeutics reported new human factors and pharmacokinetic data for Anaphylm™ (dibutepinephrine) sublingual film, supporting a planned resubmission of its New Drug Application for treatment of Type 1 allergic reactions, including anaphylaxis, in the third quarter of 2026. The company also furnished an investor presentation and a detailed press release describing these results.
In a 105-participant human factors validation study using revised packaging and instructions for use, median time to open the first pouch dropped to 3 seconds from 17 seconds in a prior study, while participants with difficulty opening the pouch fell from 26 of 166 to 1 of 105. Incorrect film placement decreased from 20 of 166 to 2 of 105, with no cases of chewing or removing the film. In a PK study, self-administered Anaphylm achieved a geometric mean Cmax of 391.7 pg/mL with a median Tmax of 12 minutes, comparable to clinician-administered Anaphylm and manual intramuscular epinephrine. Purposeful misplacement on top-of-tongue produced a geometric mean Cmax of 112.7 pg/mL, a median Tmax of 35 minutes, and clinically meaningful pharmacodynamic responses. No serious adverse events or discontinuations were reported, and the company is also advancing regulatory submissions for Anaphylm in Canada, the UK and the European Union.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership in Aquestive Therapeutics, Inc. common stock. BlackRock reports beneficial ownership of 7,992,647 shares, representing 6.4% of the outstanding common stock.
BlackRock has sole voting power over 7,885,637 shares and sole dispositive power over 7,992,647 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no individual client holds more than 5% of the outstanding common shares.
Daniel Barber, President and CEO of Aquestive Therapeutics, sold a total of 25,000 shares of common stock in open-market or private transactions on July 15–16, 2026, at prices between $4.00 and $4.04 per share, under a Rule 10b5-1 trading plan, and now directly holds 610,574 shares.
Daniel R. Barber submitted a notice relating to Aquestive Therapeutics (AQST) common stock, indicating an intention to sell 25,000 shares through Morgan Stanley Smith Barney LLC on or after 07/15/2026 on NASDAQ. These shares trace to 25,000 Restricted Stock Units acquired from the issuer on 03/09/2024. Over the prior three months, transactions labeled as 10b5-1 Sales show sales of 25,000 shares on 06/15/2026 and 8,257 shares on 05/15/2026, for amounts of 104010.00 and 35413.45, respectively.
Aquestive Therapeutics filed a resale prospectus registering 230,271 shares of Common Stock (the “Warrant Shares”) for resale by selling stockholders under a shelf registration. The Warrant Shares are issuable upon exercise of warrants issued in connection with a Tranche A term loan; the warrants are exercisable beginning May 12, 2026 and expire May 12, 2031.
The warrants carry an exercise price of $4.18 per share (Tranche A VWAP) and include a 4.99% beneficial ownership limitation (9.99% possible after notice and a 61-day delay). Aquestive is not selling any shares here and will only receive cash proceeds if warrants are exercised for cash; cashless exercises yield no proceeds to the company.
Aquestive Therapeutics files a resale prospectus registering up to 230,271 shares of Common Stock (the “Warrant Shares”) for resale by selling stockholders. The Warrant Shares are issuable upon exercise of warrants issued in connection with a $55.0M Tranche A term loan under a credit facility of up to $150.0M. The warrants have an exercise price of $4.18 per share (the Tranche A VWAP), became exercisable on May 12, 2026 and expire on May 12, 2031. Holders may elect cash or cashless exercise; the Company will receive cash proceeds only on cash exercises. The warrants include a Beneficial Ownership Limitation of 4.99% (or 9.99% if elected, effective 61 days after notice). The prospectus registers resale by multiple Oaktree-related selling stockholders and notes 125,466,988 shares outstanding as of June 18, 2026.